Business
Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis
Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis.
About this update from Avenir Wellness Solutions Inc.
[{"type":"text","content":"\n\n OXNARD, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Oak Therapeutics, a subsidiary of CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, has completed an in vivo study that compared the pharmacokinetics of its proprietary 300mg Isoniazid (INH) oral dissolvable strip (ODS) as an anti-tuberculosis (TB) treatment option against an existing commercial tablet. Completion of the in vivo study was a critical milestone of the Oak Therapeutics’ Small Business Innovative Research (SBIR) Contract from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) Phase I project “Oral Dissolving Strips for the Delivery of Isoniazid in Children and Adults.”\n Tuberculosis is one of the deadliest diseases with one third of the world’s population infected with TB, including 480,000 cases of multidrug resistant TB. The disease is nearly always curable if patients are treated with effective, uninterrupted anti-tuberculous therapy. Adherence to treatment is critical for cure of individual patients, controlling spread of infection, and minimizing the development of drug resistance.  ODS improves adherence by creating a better patient experience. They quickly melt in the mouth releasing the medicine that is easily carried in the saliva and swallowed. There are no liquids to measure, making dosing more accurate, and the bad taste of the medicine is masked with flavors and sweeteners, making the medicine much more pleasant for patients to take. The in vivo study in canines showed that the INH ODS candidate entered the bloodstream at a statistically similar rate to those of comparable commercial tablets. This confirms that ODS not only provides a better experience in delivery but that they are an effective alternative to existing tablets and liquids. “These in vivo study results represent a crucial milestone in Phase 1 of our SBIR Contract with NIAID,” said Edward Maliski, - President (pro temp) of Oak Therapeutics. “Given that we have now successfully established the technical merit, feasibility and commercial potential for the reformulation of INH as an ODS. As a result, Oak has been invited to submit a proposal for Phase II of this project, bringing us one step closer to commercializing an ODS treatment...